Protriptyline hydrochloride

Names

[ Name ]:
Protriptyline hydrochloride

[Synonym ]:
5-(3-Methylaminopropyl)-5H-dibenzo[a,d]cycloheptene Hydrochloride
5-[3-(Methylamino)propyl]-5H-dibenzo[a,d]cycloheptene hydrochloride
N-Methyl-5H-dibenzo[a,d]cycloheptene-5-propanamine Hydrochloride
3-(5H-Dibenzo[a,d][7]annulen-5-yl)-N-methylpropan-1-aminhydrochlorid
{5-[3-(Methylamino)propyl]-5H-dibenzo[a,d]cycloheptene} hydrochloride
3-(5H-Dibenzo[a,d][7]annulen-5-yl)-N-methylpropan-1-amine hydrochloride (1:1)
3-(5H-dibenzo[a,d][7]annulen-5-yl)-N-methylpropan-1-amine hydrochloride
3-(5H-dibenzo[a,d][7]annulén-5-yl)-N-méthylpropan-1-amine chlorhydrate
7-(3-Methylaminopropyl)-1,2:5,6-dibenzocycloheptatriene Hydrochloride
Protriptyline Hydrochloride
3-(5H-Dibenzo[a,d][7]annulen-5-yl)-N-methyl-1-propanamine hydrochloride (1:1)
5H-dibenzo[a,d]cycloheptene-5-propanamine, N-methyl-, hydrochloride
5H-Dibenzo[a,d]cycloheptene-5-propanamine, N-methyl-, hydrochloride (1:1)

Biological Activity

[Description]:

Protriptyline is a tricyclic antidepressant (TCA), specifically a secondary amine, for the treatment of depression and ADHD. Unique among the TCAs, protriptyline tends to be energizing instead of sedating, used for narcolepsy to achieve a wakefulness-promoting effect.

[Related Catalog]:

Signaling Pathways >> Neuronal Signaling >> AChE

Research Areas >> Neurological Disease

[Related Small Molecules]

Chemical & Physical Properties

[ Boiling Point ]:
407.7ºC at 760 mmHg

[ Melting Point ]:
169-171°

[ Molecular Formula ]:
C₁₉H₂₂ClN

[ Molecular Weight ]:
299.838

[ Flash Point ]:
198.3ºC

[ Exact Mass ]:
299.144073

[ PSA ]:
12.03000

[ LogP ]:
5.49480

[ Vapour Pressure ]:
7.41E-07mmHg at 25°C

[ Storage condition ]:
2-8°C

[ Water Solubility ]:
H2O: soluble50mg/mL

MSDS

Click to get detail MSDS

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :: HP1400000

CHEMICAL NAME :: 5H-Dibenzo(a,d)cyclohepten-5-propylamine, N-methyl-, hydrochloride

CAS REGISTRY NUMBER :: 1225-55-4

LAST UPDATED :: 199609

DATA ITEMS CITED :: 13

MOLECULAR FORMULA :: C19-H21-N.Cl-H

MOLECULAR WEIGHT :: 299.87

WISWESSER LINE NOTATION :: L C676 BHJ B3M1 &GH

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 299 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: TXAPA9 Toxicology and Applied Pharmacology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1959- Volume(issue)/page/year: 18,185,1971

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 44 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: 27ZQAG "Psychotropic Drugs and Related Compounds," 2nd ed., Usdin, E., and D.H. Efron, Washington, DC, 1972 Volume(issue)/page/year: -,88,1972

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 211 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: TXAPA9 Toxicology and Applied Pharmacology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1959- Volume(issue)/page/year: 18,185,1971

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 85 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Behavioral - changes in motor activity (specific assay) Nutritional and Gross Metabolic - body temperature decrease

REFERENCE :: PHMGBN Pharmacology: International Journal of Experimental and Clinical Pharmacology. (S. Karger AG, Postfach CH-4009 Basel, Switzerland) V.1- 1968- Volume(issue)/page/year: 12,39,1974

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 192 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: 27ZQAG "Psychotropic Drugs and Related Compounds," 2nd ed., Usdin, E., and D.H. Efron, Washington, DC, 1972 Volume(issue)/page/year: -,88,1972

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 49 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: APTOA6 Acta Pharmacologica et Toxicologica. (Copenhagen, Denmark) V.1-59, 1945-86. For publisher information, see PHTOEH Volume(issue)/page/year: 24,121,1966

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 400 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: 27ZQAG "Psychotropic Drugs and Related Compounds," 2nd ed., Usdin, E., and D.H. Efron, Washington, DC, 1972 Volume(issue)/page/year: -,88,1972

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rabbit

DOSE/DURATION :: 310 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: 27ZQAG "Psychotropic Drugs and Related Compounds," 2nd ed., Usdin, E., and D.H. Efron, Washington, DC, 1972 Volume(issue)/page/year: -,88,1972

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rabbit

DOSE/DURATION :: 8200 ug/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: 27ZQAG "Psychotropic Drugs and Related Compounds," 2nd ed., Usdin, E., and D.H. Efron, Washington, DC, 1972 Volume(issue)/page/year: -,88,1972

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - guinea pig

DOSE/DURATION :: 180 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: 27ZQAG "Psychotropic Drugs and Related Compounds," 2nd ed., Usdin, E., and D.H. Efron, Washington, DC, 1972 Volume(issue)/page/year: -,88,1972

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - guinea pig

DOSE/DURATION :: 21 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: 27ZQAG "Psychotropic Drugs and Related Compounds," 2nd ed., Usdin, E., and D.H. Efron, Washington, DC, 1972 Volume(issue)/page/year: -,88,1972 *** REVIEWS *** TOXICOLOGY REVIEW IDPYAK Industrial Pharmacology. (Mount Kisco, NY) V.1-3, 1974-79. Discontinued. Volume(issue)/page/year: 2,209,1975 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X5614 No. of Facilities: 9 (estimated) No. of Industries: 1 No. of Occupations: 1 No. of Employees: 166 (estimated) No. of Female Employees: 105 (estimated)

Safety Information

[ Symbol ]:

GHS06

[ Signal Word ]:
Danger

[ Hazard Statements ]:
H301-H312-H315-H319-H332-H335

[ Precautionary Statements ]:
P261-P280-P301 + P310-P305 + P351 + P338

[ Personal Protective Equipment ]:
dust mask type N95 (US);Eyeshields;Faceshields;Gloves

[ Hazard Codes ]:
Xn: Harmful;

[ Risk Phrases ]:
20/21/22-36/37/38

[ Safety Phrases ]:
26-36-45-36/37-16-7

[ RIDADR ]:
UN 3249

[ RTECS ]:
HP1400000

[ Packaging Group ]:
III

[ Hazard Class ]:
6.1(b)

Articles

In pursuit of drugs for American trypanosomiasis: evaluation of some "standards" in a mouse model.

Proc. Soc. Exp. Biol. Med. 216(3) , 424-8, (1997)

Forty-nine "standard" compounds known to be useful in the treatment of other diseases were tested for their suppressive activity against the trypomastigotes of Trypanosoma cruzi-infected mice. The mos...

Protriptyline, chronic tension-type headaches, and weight loss in women.

Headache 37(7) , 433-6, (1997)

Twenty-five women with chronic tension-type headaches were treated with protriptyline for 3 months, with attention paid to days of monthly headaches before and while taking the medication, as well as ...

Nocturnal respiratory failure as an indication of noninvasive ventilation in the patient with neuromuscular disease.

Respiration 64 Suppl 1 , 35-8, (1997)

Patients with neuromuscular disease may suffer from nocturnal respiratory failure despite normal daytime respiratory function. The physiological reduction in muscle tone during sleep may be life-threa...